Invesco India Pharma and Healthcare Fund Direct Growth NAV today
AMFI: 154547ISIN: INF205KA1BX5MUTF_IN: INVE_INDI_PHRM_13UMNZDInvesco Mutual FundSectoral / Thematic funds
NAV ₹9.5600up ₹0.11 (1.16%)
NAV for 29 Oct 2026, against 27 Oct 2026. Declared once a day.
Other plans: Regular IDCW ₹9.5400 · Regular Growth ₹9.5400, 1.27% · Direct IDCW ₹9.5700
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month. Assets under management in the glossary
- ₹436 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it. Total expense ratio: how it is worked out
- 3.30%26 Oct 2026
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot pull the fund's P/E down. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted. P/E in the glossary
- 55.630 Sep 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures. Holdings in the glossary
- 1330 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer. Launch date in the glossary
- 7 Sep 2026
Invesco India Pharma and Healthcare Fund returns
Direct Growth plan
Over each window to 29 Oct 2026
| Over | Direct GrowthTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). Trailing return: how it is worked out | Regular Growth | Rank in categoryRank in category. The fund's place among the funds of its category with a return over the same window, highest return first. Rank in category in the glossary | Category medianCategory median. The middle return of the funds in the category over the same window: half returned more, half less. Category median in the glossary | Middle halfMiddle half of the category. The returns of the fund a quarter of the way down the category and the fund a quarter of the way up, over the same window: half the category's funds returned between the two. Middle half of the category in the glossary |
|---|---|---|---|---|---|
| 1 week | +6.58% | +6.59% | – | – | – |
| 1 month | −3.04% | −3.15% | 181 of 254 | −1.85% | −3.3% to −0.9% |
| 3 months | Needs 3 months | – | – | −4.99% | −6.5% to −2.1% |
| 6 months | Needs 6 months | – | – | −0.82% | −3.7% to +6.2% |
| 1 year | Needs a year | – | – | −3.20% | −8.1% to +3.8% |
| 3 years | Needs 3 years | – | – | +13.29% | +9.5% to +18.4% |
| 5 years | Needs 5 years | – | – | +11.34% | +8.8% to +15.7% |
| 10 years | Needs 10 years | – | – | +14.17% | +11.9% to +15.8% |
₹10,000 put in on 10 Sep 2026 is ₹9,541 at the NAV of 29 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load. Growth of ₹10,000 in the glossaryOver a year and longer, a return is the yearly rate. Rank, median and middle half among the Direct plans of Sectoral / Thematic funds, each fund's return to its latest NAV on or before 29 Oct 2026.
Invesco India Pharma and Healthcare Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies. Expense ratio, 30-day average in the glossary
- 2.94%Over the last 30 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan at its highest since Sep 2026 in the latest month.Direct plan lowest 0.59%, Sep 2026.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. Base expense ratio in the glossary | 0.50% | |
| Brokerage | 0.86% | |
| Transaction costs | 0.05% | |
| Statutory levies | 1.89% |
Per cent of assets a year, filed for 26 Oct 2026. The parts add up to that day's total.
Exit load, in the fund house's words
Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services TaxMoreLess
Buying and selling
- Lump-sum purchases
- Accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase. Minimum investment in the glossary
- ₹1,000
- Minimum top-up
- ₹1,000
- Minimum redemption
- ₹1,000
- SIP
- Accepted
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold. Lock-in in the glossary
- None
- SIP minimum
- Daily/Weekly/Monthly-Rs100, Quarterly: Rs 300, Fixed
- SIP instalments, at least
- Daily - 60 installments, Weekly/Monthly - 12 installments ; Quaterly- 4 installments
As listed for this plan on 30 Oct 2026.
How Invesco India Pharma and Healthcare Fund is taxed
Taxed as an equity fund where it keeps 65% or more in shares of listed Indian companies: gains on units held over 12 months are taxed at 12.5% above ₹1.25 lakh a year, and gains on units held 12 months or less at 20%. Otherwise, gains on units held over 24 months are taxed at 12.5%, and gains on units held 24 months or less at the income tax slab rate.
IDCW payouts are added to the holder's income and taxed at the income tax slab rate. The fund deducts 10% tax at source for a resident when its payouts to them in a year counted from April to March are above ₹10,000.
Rules in force from 1 Apr 2025, checked 27 Oct 2026. Surcharge and cess are not included.
Invesco India Pharma and Healthcare Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹111 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors. Share of assets in the direct plans in the glossary
- 13.6%Of the quarter's average
Invesco India Pharma and Healthcare Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. Large, mid and small cap in the glossary | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. Weight in the fund in the glossary | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. Held since in the glossary | |||
|---|---|---|---|---|---|
| Max Healthcare InstituteHealthcare Services | Mid cap111th | 9.58% | 41.72 | 4,48,697 | Sep 2026or earlier |
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 8.99% | 39.17 | 2,15,600 | Sep 2026or earlier |
| Sai Life SciencesPharmaceuticals & Biotechnology | Small cap329th | 8.63% | 37.58 | 2,46,478 | Sep 2026or earlier |
| Apollo Hospitals EnterpriseHealthcare Services | Large cap97th | 8.03% | 34.96 | 42,818 | Sep 2026or earlier |
| Manipal Health EnterprisesHealthcare Services | 7.98% | 34.74 | 4,90,483 | Sep 2026or earlier | |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 7.85% | 34.17 | 36,777 | Sep 2026or earlier |
| Global HealthHealthcare Services | Small cap262nd | 7.00% | 30.47 | 2,23,244 | Sep 2026or earlier |
| Dr. Agarwal's Health CareHealthcare Services | Small cap442nd | 6.32% | 27.54 | 5,74,524 | Sep 2026or earlier |
| CORONA RemediesPharmaceuticals & Biotechnology | Small cap566th | 6.13% | 26.70 | 1,27,543 | Sep 2026or earlier |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 4.93% | 21.45 | 44,689 | Sep 2026or earlier |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | Mid cap176th | 4.86% | 21.18 | 90,716 | Sep 2026or earlier |
| Krishna Institute of Medical SciencesHealthcare Services | Small cap285th | 4.72% | 20.57 | 2,75,638 | Sep 2026or earlier |
| Aster DM Quality CareHealthcare Services | Mid cap244th | 1.99% | 8.67 | 1,24,423 | Sep 2026or earlier |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| Triparty Repo | 20.56% | 89.55 |
| Net Receivables / (Payables) | −7.57% | −32.96 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions. Largest holding in the glossary
- 9.58%Max Healthcare Institute
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions. Top 5 holdings in the glossary
- 43.21%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions. Top 10 holdings in the glossary
- 75.44%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights. Effective number of holdings in the glossary
- 11.9Taken over 87.01% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought. Asset allocation in the glossary- Indian shares87.01%
- Cash and receivables12.99%
Per cent of the fund's net assets.
Large, mid and small cap
- Large cap34.25%Category 49.50%
- Mid cap18.88%Category 21.62%
- Small cap37.70%Category 26.68%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026. Shares not on the list: 7.98% of the fund. Category is the average of 249 Sectoral / Thematic funds.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets. Sector weight in the glossary1sector
- Healthcare87.01%Category 12.70%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026. Category is the average of 254 Sectoral / Thematic funds. Category average. The sector's weight, less the futures sold on it, averaged over the 254 Sectoral / Thematic funds that disclosed a portfolio for Sep 2026. A fund holding none of the sector counts as 0.
Risk ratios
NAV to 29 Oct 2026
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. Largest fall in the glossary | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. Back at the high in the glossary |
|---|---|---|---|---|
| Since Sep 2026 | −11.39% | 23 Sep 2026 | 23 Oct 2026 | Not yet |
Portfolio turnover
- Year to Sep 2026Portfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it. Portfolio turnover in the glossary
- 0.0%
Invesco India Pharma and Healthcare Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. Return in the manager's time in the glossary | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. Benchmark over the same days in the glossary | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. Difference from the benchmark in the glossary | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. Portfolio changed after the handover in the glossary | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. Portfolio changed before the handover in the glossary | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. Assets the manager runs in the glossary | ||
|---|---|---|---|---|---|---|---|---|
| Aditya KhemaniPrimary: | Sep 2026 | −8.98%over 46 days | – | – | – | – | 6 | ₹46,183 Cr₹29,736 Cr alone |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | |||||
|---|---|---|---|---|---|
| Invesco India Small Cap FundAditya Khemani | Nov 2023 | +17.50%a year | – | – | ₹16,131 Cr |
| Invesco India Mid Cap FundAditya Khemani | Nov 2023 | +19.46%a year | – | – | ₹15,749 Cr |
| Invesco India Large & Mid Cap FundAditya Khemani | Nov 2023 | +18.61%a year | +10.09% | +8.52 pts | ₹12,178 Cr |
| Invesco India Business Cycle FundAditya Khemani | Feb 2025 | +23.07%a year | +6.18% | +16.89 pts | ₹1,373 Cr |
| Invesco India Technology FundAditya Khemani | – | – | – | ₹317 Cr |
The ten largest by assets, by manager. Returns are the direct plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. Portfolio overlap in the glossary | Shared holdings. The number of securities both funds hold, cash and futures left out. Shared holdings in the glossary | |
|---|---|---|
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 43.12% | 9 |
| LIC MF Healthcare FundLIC Mutual Fund | 40.16% | 9 |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 39.96% | 10 |
| PGIM India Healthcare FundPGIM India Mutual Fund | 39.20% | 9 |
| ITI Pharma and Healthcare FundITI Mutual Fund | 39.00% | 9 |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 38.60% | 11 |
| WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund | 35.29% | 10 |
| Kotak Healthcare FundKotak Mahindra Mutual Fund | 35.26% | 8 |
| Baroda BNP Paribas Health and Wellness FundBaroda BNP Paribas Mutual Fund | 32.94% | 7 |
| Bandhan Healthcare FundBandhan Mutual Fund | 32.70% | 8 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Overlap with the fund house's other funds
| Invesco India Mid Cap FundInvesco Mutual Fund | 24.23% |
| Invesco India Large & Mid Cap FundInvesco Mutual Fund | 22.26% |
| Invesco India Business Cycle FundInvesco Mutual Fund | 19.81% |
| Invesco India Small Cap FundInvesco Mutual Fund | 19.13% |
| Invesco India Consumption FundInvesco Mutual Fund | 13.49% |
| Invesco India Multi Cap FundInvesco Mutual Fund | 12.85% |
| Invesco India Manufacturing FundInvesco Mutual Fund | 10.64% |
| Invesco India ESG Integration Strategy FundInvesco Mutual Fund | 9.42% |
| Invesco India Flexi Cap FundInvesco Mutual Fund | 9.20% |
| Invesco India ELSS Tax Saver FundInvesco Mutual Fund | 8.06% |
As the fund house states it, for Sep 2026.
Changes to the fund
Newest first.
2026
- 11 SepTermsSIP instalments: not accepted to accepted
Fund details
Objective
To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Asset allocation
- Equity and Equity related instruments of companies in the Pharma, Healthcare and allied sectors : Min. 80% Max 100% ;
- Other equity and equity related instruments : Min. 0% Max 20% ;
- Money Market / Other Liquid Instruments : Min. 0% Max 20% ;
- Gold / Silver ETFs : Min. 0% Max. 20% ;
- Units issued by InvITs : Min. 0% Max 10%
Type of scheme
An open ended equity scheme investing in Pharma, Healthcare and allied sectors
- Stated category
- Sectoral Fund
- BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. Benchmark in the glossary
- BSE Healthcare TRI
- Second benchmarkSecond benchmark. An additional index the fund house chose to compare the fund with, beside the first benchmark, which every fund of its category shares. Second benchmark in the glossary
- Nifty 50 TRI
- Risk level at launchRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. Riskometer in the glossary
- Very High
- New fund offer
- 18 Aug 2026 to 1 Sep 2026
- Units first allotted
- 7 Sep 2026
- Open for sale again
- 11 Sep 2026
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹1,000
Plans and codes
| Plan | AMFI code | ISIN | ISIN, reinvestment | MUTF_IN | First NAV |
|---|---|---|---|---|---|
| Direct Growth | 154547 | INF205KA1BX5 | INVE_INDI_PHRM_13UMNZD | 10 Sep 2026 | |
| Regular Growth | 154545 | INF205KA1BU1 | INVE_INDI_PHRM_10C3KVV | 10 Sep 2026 | |
| Direct IDCW | 154546 | INF205KA1BY3 | INF205KA1BZ0 | INVE_INDI_PHRM_KMA7YU | 10 Sep 2026 |
| Regular IDCW | 154544 | INF205KA1BV9 | INF205KA1BW7 | INVE_INDI_PHRM_58SI3N | 10 Sep 2026 |
This fund
- Scheme information documentThe fund's objective, terms, costs and risks in full
Factsheet
- Factsheet - September 2026Invesco Mutual Fund, Sep 2026
Statement of additional information
- SAI Invesco Mutual FundInvesco Mutual Fund, Oct 2026
Annual report
- Annual Report for FY 2025-26Invesco Mutual Fund, Mar 2026
- Abridged Annual Report (2025-2026) Fixed Income SchemesInvesco Mutual Fund, Mar 2026
Riskometer disclosure
- Invesco MF - Risk-O-Meter Disclosure FY 25-26Invesco Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Portfolio Overlap - September 2026Invesco Mutual Fund, Sep 2026